Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
NCT ID NCT04294498
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests whether the immunotherapy drug durvalumab can be safely given to people with advanced liver cancer who also have an active hepatitis B infection. All participants receive an antiviral drug (entecavir) to control the hepatitis B virus. The main goal is to see if durvalumab causes the virus to reactivate or leads to liver inflammation. The trial enrolls 30 adults with confirmed liver cancer and active hepatitis B.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab (an immunotherapy drug) given alongside entecavir (an antiviral drug)
- What this could lead to
- If successful, this could expand treatment options for liver cancer patients who also have active hepatitis B, without requiring strict viral suppression beforehand.
- What could go wrong
- This is a small, early-phase study (30 participants) focused on safety, not yet proving the drug works against the cancer. There is still a risk of hepatitis B flare-ups or other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer
- New drug zanzalintinib tested for advanced liver cancer
- New drug cocktail shows promise for tough liver cancer
- Promising drug cocktail targets Hard-to-Treat liver cancer
- Virus therapy takes on liver cancer in major trial
- Immune drug plus targeted chemo shows promise for liver cancer in early trial